Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ. Perez OD, et al. Among authors: inagaki a. Mol Ther. 2012 Sep;20(9):1689-1698. doi: 10.1038/mt.2012.83. Epub 2012 May 1. Mol Ther. 2012. PMID: 22547150 Free PMC article.
Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Takahashi M, Valdes G, Hiraoka K, Inagaki A, Kamijima S, Micewicz E, Gruber HE, Robbins JM, Jolly DJ, McBride WH, Iwamoto KS, Kasahara N. Takahashi M, et al. Among authors: inagaki a. Cancer Gene Ther. 2014 Oct;21(10):405-410. doi: 10.1038/cgt.2014.38. Epub 2014 Oct 10. Cancer Gene Ther. 2014. PMID: 25301172 Free PMC article.
Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, Takahashi M, Matsumoto H, Hacke K, Kruse CA, Ostertag D, Robbins JM, Gruber HE, Jolly DJ, Kasahara N. Hiraoka K, et al. Among authors: inagaki a. Neuro Oncol. 2017 Jul 1;19(7):918-929. doi: 10.1093/neuonc/nox038. Neuro Oncol. 2017. PMID: 28387831 Free PMC article.
Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
Inoko K, Hiraoka K, Inagaki A, Takahashi M, Kushibiki T, Hontani K, Takano H, Sato S, Takeuchi S, Nakamura T, Tsuchikawa T, Shichinohe T, Gruber HE, Jolly DJ, Kasahara N, Hirano S. Inoko K, et al. Among authors: inagaki a. Cancer Gene Ther. 2018 Aug;25(7-8):184-195. doi: 10.1038/s41417-018-0020-7. Epub 2018 May 8. Cancer Gene Ther. 2018. PMID: 29735994
PET imaging for gene & cell therapy.
Collins SA, Hiraoka K, Inagaki A, Kasahara N, Tangney M. Collins SA, et al. Among authors: inagaki a. Curr Gene Ther. 2012 Feb 1;12(1):20-32. doi: 10.2174/156652312799789271. Curr Gene Ther. 2012. PMID: 22263921 Review.
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.
Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N, Mueller BM, Kruse CA. Hickey MJ, et al. Among authors: inagaki a. Clin Cancer Res. 2013 Aug 1;19(15):4137-48. doi: 10.1158/1078-0432.CCR-12-3735. Epub 2013 Jun 18. Clin Cancer Res. 2013. PMID: 23780889 Free PMC article.
Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.
Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, Mischel PS, Gordon LK, Wadehra M. Qin Y, et al. Among authors: inagaki a. J Biol Chem. 2014 May 16;289(20):13974-85. doi: 10.1074/jbc.M113.543728. Epub 2014 Mar 18. J Biol Chem. 2014. PMID: 24644285 Free PMC article.
Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK, Tseng HC, Kaur K, Topchyan P, Inagaki A, Bui VT, Kasahara N, Cacalano N, Jewett A. Kozlowska AK, et al. Among authors: inagaki a. Cancer Immunol Immunother. 2016 Sep;65(9):1085-97. doi: 10.1007/s00262-016-1866-x. Epub 2016 Jul 20. Cancer Immunol Immunother. 2016. PMID: 27439500 Free PMC article.
374 results